Abstract | BACKGROUND:
Therapy with sofosbuvir-ledipasvir (SOF-LDV) has been very effective in chronic HCV genotype-1 in clinical trials and several real-world cohorts. However, the safety and efficacy data of SOF-LDV for HCV genotype-6 is quite limited. METHODS: This open-label, clinical experience evaluated the safety and efficacy of SOF-LDV with or without ribavirin (RBV) for 12-24 weeks in patients with HCV genotype-1 (n=356) and genotype-6 (n=175) in Vietnam between September 2015 and May 2017. RESULTS: Among 539 patients evaluated for therapy, 531 patients completed treatment with either SOF-LDV for 12 weeks (n=284); SOF-LDV + RBV for 12 weeks (n=109); SOF-LDV for 24 weeks (n=36); or SOF-LDV + RBV for 24 weeks (n=102). 45% were male with a mean age of 56.3 (range 20-87) years. The mean HCV RNA was 4,370,000 IU/ml and 72.7% had high viral load of >800,000 IU/ml. 17.3% failed prior interferon-based therapy and 52.5% had advanced fibrosis (F3-4) as noted by transient elastography. The overall sustained virological response (SVR12) rate was 99.6% (529/531). Virological relapses occurred in two patients with genotype-1 in the SOF-LDV for 12 weeks and SOF-LDV + RBV for 24 weeks treatment groups. There was no significant difference in demographic data and treatment outcomes between patients with genotype-1 versus 6. Adverse events were mild with all SOF-LDV regimens, but appeared to be more common with 24-week treatment groups. CONCLUSIONS: SOF-LDV with or without RBV was highly effective and safe in Vietnamese patients with HCV genotype-1 and 6.
|
Authors | Pham Thi Thu Thuy, Chalermrat Bunchorntavakul, Ho Tan Dat, Julia Palecki, K Rajender Reddy |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 23
Issue 5
Pg. 415-423
( 2018)
ISSN: 2040-2058 [Electronic] England |
PMID | 29303482
(Publication Type: Clinical Study, Journal Article)
|
Chemical References |
- Antiviral Agents
- Benzimidazoles
- Fluorenes
- RNA, Viral
- ledipasvir, sofosbuvir drug combination
- Ribavirin
- Uridine Monophosphate
- Sofosbuvir
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antiviral Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Drug Therapy, Combination
- Female
- Fluorenes
(therapeutic use)
- Genotype
- Hepacivirus
(classification, drug effects, genetics, metabolism)
- Hepatitis C, Chronic
(complications, drug therapy, pathology, virology)
- Humans
- Liver
(drug effects, pathology, virology)
- Liver Cirrhosis
(etiology, pathology, prevention & control, virology)
- Male
- Middle Aged
- Patient Safety
- RNA, Viral
(antagonists & inhibitors, genetics, metabolism)
- Recurrence
- Ribavirin
(therapeutic use)
- Sofosbuvir
- Sustained Virologic Response
- Uridine Monophosphate
(analogs & derivatives, therapeutic use)
- Vietnam
- Viral Load
(drug effects)
|